Academic · Private company
New Approaches to Neuroblastoma Therapy Consortium
Track this companyFree. Adds New Approaches to Neuroblastoma Therapy Consortium to your Dealase workspace and tells you when its record changes.
Clinical trials216 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials21
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabPHASE2 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT07261241 · fetched Nov 12, 2026
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialPHASE2 · RECRUITING · started Dec 16, 2024ClinicalTrials.gov NCT06450041 · fetched Nov 12, 2026
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsPHASE1 · ACTIVE_NOT_RECRUITING · started Jan 14, 2019ClinicalTrials.gov NCT02573896 · fetched Nov 12, 2026
- MIBG With Dinutuximab +/- VorinostatPHASE1 · COMPLETED · started Sep 12, 2018ClinicalTrials.gov NCT03332667 · fetched Nov 12, 2026
- NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)PHASE1 · COMPLETED · started Sep 5, 2017ClinicalTrials.gov NCT03107988 · fetched Nov 12, 2026
- Neuroblastoma Precision TrialACTIVE_NOT_RECRUITING · started Aug 22, 2016ClinicalTrials.gov NCT02868268 · fetched Nov 12, 2026
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 8, 2015ClinicalTrials.gov NCT02298348 · fetched Nov 12, 2026
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With VorinostatPHASE2 · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02035137 · fetched Nov 12, 2026
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/TopotecanPHASE1 · COMPLETED · started Jan 16, 2014ClinicalTrials.gov NCT02030964 · fetched Nov 12, 2026
- Neuroblastoma Biology StudyRECRUITING · started Jul 1, 2011ClinicalTrials.gov NCT01587300 · fetched Nov 12, 2026
- N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed NeuroblastomaPHASE1 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01019850 · fetched Nov 12, 2026
- N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk NeuroblastomaPHASE1 · COMPLETED · started Dec 1, 2009ClinicalTrials.gov NCT00885326 · fetched Nov 12, 2026
- N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk NeuroblastomaPHASE1 · COMPLETED · started Jan 1, 2007ClinicalTrials.gov NCT00509353 · fetched Nov 12, 2026
- N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant NeuroblastomaPHASE1 · COMPLETED · started Dec 1, 2006ClinicalTrials.gov NCT00646230 · fetched Nov 12, 2026
- N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent NeuroblastomaPHASE1 · COMPLETED · started Dec 1, 2005ClinicalTrials.gov NCT00295919 · fetched Nov 12, 2026
- N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk NeuroblastomaPHASE2 · COMPLETED · started Sep 1, 2005ClinicalTrials.gov NCT00253435 · fetched Nov 12, 2026
- N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant NeuroblastomaPHASE1 · COMPLETED · started May 1, 2004ClinicalTrials.gov NCT00093353 · fetched Nov 12, 2026
- N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell TransplantationPHASE1 · COMPLETED · started Mar 1, 2004ClinicalTrials.gov NCT00083135 · fetched Nov 12, 2026
- N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk NeuroblastomaPHASE1 · COMPLETED · started Aug 1, 2003ClinicalTrials.gov NCT00084422 · fetched Nov 12, 2026
- N99-02: Melphalan and Buthionine SulfoximinePHASE1 · COMPLETED · started Aug 1, 2001ClinicalTrials.gov NCT00005835 · fetched Nov 12, 2026
- Chemotherapy in Treating Children With NeuroblastomaPHASE1 · COMPLETED · started Jun 1, 1996ClinicalTrials.gov NCT00002730 · fetched Nov 12, 2026